THE WOODLANDS, Texas, July 23, 2026
Autonomix Medical, Inc. announced that it has been granted U.S. Patent No. 12,471,776, titled “ANS Assessment Systems, Kits, and Methods,” significantly expanding its intellectual property portfolio supporting next-generation precision neuromodulation technologies. The newly issued patent protects advanced systems designed to monitor physiological and electrophysiological signals for evaluating autonomic nervous system (ANS) activity, enabling more accurate assessment of sympathetic and parasympathetic nervous system function. The patented technology is intended to improve patient selection, procedural guidance, treatment feedback, and post-treatment monitoring, strengthening the company’s long-term strategy to develop innovative nerve-targeted therapies. By securing this patent, Autonomix Medical reinforces its leadership in precision medical technology while advancing solutions aimed at improving outcomes across multiple diseases involving the peripheral nervous system.
Patent Expands Precision Neuromodulation Capabilities
The newly granted patent broadly covers systems, devices, algorithms, imaging technologies, sensors, and clinical assessment methods designed to evaluate autonomic nervous system activity with greater precision than conventional approaches. The technology enables physicians to monitor physiological responses in real time during nerve-targeted procedures, helping improve treatment accuracy while providing valuable procedural feedback. According to the company, these innovations have the potential to support future neuromodulation therapies across a broad range of conditions linked to autonomic dysfunction, including cardiovascular diseases, hypertension, chronic pain disorders, and neurological conditions. The patent further strengthens the scientific foundation of Autonomix’s proprietary platform by protecting technologies that may enhance clinical decision-making throughout diagnosis, treatment, and long-term patient management.
Technology Platform Designed for Future Clinical Applications
Autonomix Medical stated that its vision extends beyond a single medical device by building a comprehensive platform capable of transforming how physicians identify and treat diseases affecting the peripheral nervous system. The company’s proprietary catheter-based system incorporates an advanced microchip sensing array capable of detecting and differentiating neural signals with significantly greater sensitivity than currently available technologies. This capability could potentially enable the first transvascular diagnosis and treatment of peripheral nervous system disorders virtually anywhere in the body. The patented assessment technologies complement this platform by helping physicians identify optimal treatment targets while improving procedural precision and therapeutic effectiveness. Company leadership believes the expanded intellectual property portfolio positions Autonomix as a leading innovator in one of the fastest-growing segments of medical device technology focused on precision nerve-targeted interventions.
Advertisement
Expanding Innovation in Pain Management and Beyond
Autonomix Medical is initially developing its investigational platform for the treatment of severe pancreatic cancer pain, an area with substantial unmet clinical need due to the limited effectiveness of existing therapies. Beyond oncology-related pain, the company believes its technology has the potential to address dozens of future clinical indications, including chronic pain management, cardiovascular disorders, hypertension, and other diseases involving autonomic nervous system dysfunction. Although the platform has not yet received U.S. regulatory clearance for commercial marketing, the newly issued patent further strengthens its competitive position by protecting key innovations supporting future product development and commercialization. As research and clinical development continue, Autonomix Medical’s expanding intellectual property portfolio provides a strong foundation for advancing precision neuromodulation technologies that could improve diagnostic accuracy, procedural efficiency, and patient outcomes across multiple therapeutic areas while supporting the future evolution of minimally invasive nerve-targeted medicine.
Source: Autonomix Medical press release
